Trial results

The Effect of Soliqua on Glucose Variability in Type 2 Patients Among South Asians

NCT03819790 on ClinicalTrials.gov · last registry update 2021-02-25

Finished 19 November 2019, after enrolling 119 people. Primary outcome, as filed: Time in range at week 13. lixisenatide is already approved in the US for type 2 diabetes, so this is asking a further question rather than establishing the drug works at all. The registry entry has been edited 1 time since then.

Status

COMPLETED

Phase

P4

Drug

lixisenatide

Soliqua, Adlyxin

Sponsor

LMC Diabetes & Endocrinology Ltd.

Sponsor type

Other

Enrollment

119

Started

2018-10-02

Primary completion

2019-11-19 actual

Observed history

Every change this record has made since we started watching it. ClinicalTrials.gov shows only the current value. When a field is edited the previous one is overwritten and nothing is published to say so, so this history exists only because someone was recording it at the time.

Primary outcome

Time in range at week 13

Conditions studied

Diabetes Mellitus, Type 2

Every field above is taken directly from the registry record. See all detected changes across the class, or the lixisenatide page for this molecule’s full trial and approval history.